{"Clinical Trial ID": "NCT00951665", "Intervention": ["INTERVENTION 1:", "Phase Ib Speed 1", "Participants received T-DM1 Q3W + paclitaxel QW intravenously.", "INTERVENTION 2:", "Phase Ib Speed 2", "Participants received T-DM1 Q3W + paclitaxel QW + pertuzumab Q3W intravenously."], "Eligibility": ["Incorporation criteria:", "\u00b7 Histologically documented HER2-positive locally advanced or metastatic breast cancer", "- Tumor tissue blocks or 15 to 20 unpreserved tissue blades for HER2 Central Laboratory State Confirmation Tests and Other Exploratory Assessments", "- Previous Trastuzumab in any treatment line (phase Ib patients only)", "No previous treatment with T-DM1 or pertuzumab", "A measurable or evaluable disease", "- Cardiac ejection fraction >=50% by echocardiogram or multigated acquisition scan", "Life expectancy >= 90 days according to the investigator's assessment", "- Exclusion criteria:", "Less than 21 days after the last anti-tumour therapy, including chemotherapy, biological, experimental, immune, hormonal or radiotherapy for the treatment of breast cancer, except for the following cases: replacement hormonal therapy or oral contraceptives are permitted; palliative radiotherapy involving <=25% of bone with the marrow is permitted if completed within 14 days prior to the first study.", "History of intolerance or hypersensitivity to trastuzumab and/or adverse events related to trastuzumab, murine proteins or any of the excipients that resulted in the definitive discontinuation of trastuzumab", "- Peripheral neuropathy of grade >= 2 by NCI CTCAE, version 3.0, at the time or within 3 weeks prior to the first study (phase Ib patients)", "- Peripheral neuropathy of grade >/=1 by NCI CTCAE, version 3.0, at or within 3 weeks prior to the first study (Phase IIa patients)", "Doxorubicin > 500 mg/m^2; Doxorubicin liposomal > 900 mg/m^2; Epirubicin > 720 mg/m^2", "Clinically significant history of cardiac dysfunction", "\u2022 Untreated or progressive brain metastases, or which have required any type of treatment (including radiation, surgery or steroids) to control the symptoms of brain metastases within 60 days of the first treatment of the study.", "\u2022 History of other malignancies over the past 5 years, with the exception of carcinomas appropriately treated in situ in the cervix, basal cell carcinoma, synchronous or subsequent HER2-positive breast cancer or other malignancies with a curative outcome similar to that expected."], "Results": ["Performance measures:", "Number of participants with adverse reactions (ARs), serious adverse reactions (ARs), grade 3/4 adverse reactions and deaths", "An EA is defined as any adverse medical occurrence in a clinical investigation participant or participant, temporally associated with the use of a drug, whether or not it is considered to be related to the drug. An EA is any adverse medical occurrence that, at any dose, results in death, threatens life, requires hospitalization or prolongation of existing hospitalization, results in disability or disability, or results in congenital anomaly or lack of birth.", "Time limit: up to 30 days after the last dose of the treatment or the discontinuation/end of the study, whichever is later:", "Results 1:", "Title of arm/group: Phase Ib Regiment 1", "The participants received T-DM1 Q3W + paclitaxel QW intravenously.", "Total number of participants analysed: 26", "Type of measurement: Number", "Unit of measurement: participants All EA: 26", "All EAS: 7", "Death: 1", "Any AE Grade 3: 19", "Any AE Grade 4: 0", "AE leading to T-DM1: 3", "AEs leading to the cessation of paclitaxel: 20", "AEs leading to stopping pertuzumab: NA [1]", "Results 2:", "Title of arm/group: Phase Ib Regiment 2", "The participants received T-DM1 Q3W + paclitaxel QW + pertuzumab Q3W intravenously.", "Total number of participants analysed: 10", "Type of measurement: Number", "Unit of measurement: participants All EA: 10", "All EAS: 5", "Death: 0", "Any AE Grade 3: 5", "Any AE Grade 4: 2", "AE leading to T-DM1: 1", "AEs leading to the cessation of paclitaxel: 7", "AEs leading to stopping pertuzumab: 1"], "Adverse Events": ["Undesirable Events 1:", "Total: 7/26 (26.92 per cent)", "Febrile neutropenia 1/26 (3.85 per cent)", "Neutropenia 0/26 (0.00 %)", "Thrombocytopenia 0/26 (0.00 %)", "Congestive heart failure 0/26 (0.00 %)", "Extrasystoles 0/26 (0.00 %)", "Nausea 1/26 (3.85 per cent)", "Abdominal pain 0/26 (0.00 %)", "Constipation 0/26 (0.00 %)", "gastrointestinal haemorrhage 0/26 (0.00 %)", "Death - unknown cause 1/26 (3.85%)", "- Thrombosis in the device 0/26 (0.00 %)", "Adverse Events 2:", "Total: 5/10 (50%)", "Febrile neutropenia 0/10 (0.00 %)", "Neutropenia 0/10 (0.00 %)", "Thrombocytopenia 1/10 (10.00%)", "- Congestive heart failure 0/10 (0.00 %)", "Extrasystoles 0/10 (0.00 %)", "- Nausea 0/10 (0.00 %)", "Abdominal pain 0/10 (0.00 %)", "Constipation 0/10 (0.00 %)", "gastrointestinal haemorrhage 0/10 (0.00 %)", "Death - unknown cause 0/10 (0.00 %)", "- Thrombosis in the device 0/10 (0.00 %)"]}